SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- Cancer

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (269)9/25/2002 1:40:08 AM
From: russet  Read Replies (1) of 1840
 
More head and neck??,...as for the body gene gun,...good thing mice are not an endangered species (ggggggg)

Dr. Burian Presents Data From 12 Primary Head and Neck Cancer Patients Treated With Genetronics' Electroporation Therapy

SAN DIEGO, Sept. 24 /CNW/ -- Genetronics Biomedical
Corporation, San Diego, (Amex: GEB; Toronto) announced that Dr. Martin Burian
of the University of Vienna, presented an abstract at the American Academy of
Otolaryngology - Head and Neck Surgery Foundation, Inc. annual meeting today
in San Diego, California.
The abstract, entitled "Electroporation Therapy in Head and Neck Cancer,"
gives an overview of a study in which 12 patients diagnosed with primary head
and neck cancer were treated with Genetronics' proprietary Electroporation
Therapy (EPT) system. Four weeks after the treatment, the treated area and a
save margin were excised and analyzed. In 10 out of the 12 patients there was
no evidence of disease in the excised tissue, demonstrating a complete
response rate of 83% in the patients treated. The conclusion of the abstract
was that, "EPT seems to serve as an interesting alternative in the treatment
of head and neck cancer."

About Genetronics
Genetronics Biomedical Corporation is the world leader in electroporation
therapy with 216 patents issued, allowed, or pending. The Company utilizes
its proprietary electroporation technology for the targeted intracellular
delivery of therapeutic materials, concentrating on drugs, vaccines, and gene
therapy. In oncology, Genetronics has initiated Phase III clinical trials for
the treatment of recurrent head & neck cancer. In gene therapy, Genetronics
has several collaborations with major biotechnology and pharmaceutical
companies for the delivery of therapeutic genes or vaccines using
electroporation. More information can be obtained at

http://www.genetronics.com

Edit,...the website is still under construction (gggggg)

For further information: investors, Clarke Galvin or Karl Cahill of
Genetronics Biomedical Corporation, +1-858-597-6006
/Web site: genetronics.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext